MTOR and neoplasm: After inhibiting the AKT/mTOR pathway, although the drug-resistant mutant (mTorRR) CAR–T cells can be tolerated, bystander immune cell function remains suppressed, thereby impeding tumor cell clearance and potentially compromising therapeutic efficacy.